How Moderna is Helping Advance the Fight Against Cancer
December 18, 2023
Last week, we announced follow-up data from our phase 2b study evaluating our investigational individualized neoantigen therapy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with high-risk melanoma following complete resection. Watch the next installment of our IR Insights video series to hear more from Dr. Stephen Hoge, Moderna’s president, and Dr. Kyle Holen, our Head of Development in Oncology and Therapeutics.